A deep dive into research reveals essential findings on the dynamics and economic burdens of SARS-CoV-2 infections within hospitals, crucial knowledge for those invested in infection prevention. The study involved a thorough retrospective analysis of SARS-CoV-2 infections from March 2020 to June 2021 in two secondary care hospitals in Germany. It focused on elucidating the impact of patient infections, staff infections, nosocomial infections leading to outbreaks, and the economic implications of these outbreaks.
The study found that a total of 396 patients, infected with SARS-CoV-2, received care in the two hospitals under consideration. Risk factors for severe disease and mortality were directly proportional to factors such as age, male gender, and a high CRB-65 score. Dyspnoea presented as the most often-reported symptom. Strikingly, 65 patients within the study perished, with most of these deaths occurring in the second pandemic wave.
In terms of hospital staff, 12.5 percent were infected during the three waves. Nurses and other healthcare workers on regular wards bore the brunt of the occupational risk of infection during outbreaks. Furthermore, the study identified 11 hospital outbreaks leading to profound economic implications for these healthcare institutions through resultant loss of workforce, temporary ward closures, blocked beds, decreased patient intake, and a surge in personnel costs.
The revelation of these findings underscores the significance of continuously adapting infection prevention strategies to safeguard hospitals as combating zones for patients and the staff alike. More analysis concerning the varied pandemic waves and implemented infection prevention strategies is essential to pinpoint vulnerabilities and ensure those hallmarks are prevented in future predicaments. The study was conducted in compliance with the Declaration of Helsinki and national standards and was approved by the ethics committee of the Chamber of Physicians Westphalia-Lippe and University of Münster. It was officially registered on 25th August 2021 at the German Clinical Trials Register.
Source: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09641-1